ArticleCurrent medical imaging2026
Superselective Lipiodol CT-guided Microwave Ablation for Small Hepatocellular Carcinoma: A Novel Imaging Guidance Strategy.
Article in Current medical imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionMicrowave Ablation (MWA) is a well-established curative therapy for early-stage Hepatocellular Carcinoma (HCC). However, conventional NonContrast CT (NCCT) guidance for MWA faces limitations, including poor visualization of isodense lesions and significant needle artifacts, which can compromise targeting accuracy. This study evaluated a novel imaging-guidance strategy utilizing superselective lipiodol CT to explore its feasibility in addressing these challenges. MATERIALS AND
methodsTreatment-naive patients with BCLC 0/A HCC within the Milan criteria were included in this retrospective study. All patients underwent superselective transarterial lipiodol-only marking followed by CT-guided MWA within 1 week. Treatment efficacy was evaluated based on technical success, Local Tumor Progression (LTP), Intrahepatic Distant Recurrence (IDR), Recurrence-Free Survival (RFS), and Overall Survival (OS). Imaging-guidance performance was descriptively evaluated based on intraprocedural lesion visualization and operator-adjusted window settings used to facilitate needle positioning.
resultsForty-five patients with 57 lesions were enrolled. The mean lesion diameter was 18.2 ± 8.8 mm. The initial technical success rate was 95.5% (43/45). The 1-, 2-, and 3-year rates were: LTP: 2.2%, 4.4%, 4.4%; IDR: 24.4%, 37.7%, 44.4%; RFS: 68.9%, 52.7%, 38.2%; OS: 85.1%, 72.4%, and 60.5%. During lipiodol CT-guided procedures, lesions that were isodense and poorly visualized on pre-procedural NCCT were identifiable to the operator, and the window level settings used for final needle positioning confirmation had a mean value of 252.2 ± 75.8 Hounsfield Units DISCUSSION: The superselective lipiodol CT guidance strategy demonstrated feasibility in addressing several practical limitations of conventional NCCT. It allowed visualization of otherwise inconspicuous isodense lesions, supported needle positioning under reduced metallic artifact conditions at empirically adjusted window levels, and aided the visualization of adjacent portal vein branches during the procedure. This approach utilizes Lipiodol primarily as a long-lasting contrast agent for enhanced CT visualization, rather than for its chemotherapeutic or embolic effect.
conclusionSuperselective lipiodol CT guidance is a feasible imaging approach for intraprocedural lesion visualization and needle positioning during MWA of small HCC in selected procedural scenarios. Controlled comparative or quantitative validation studies are warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.